(Glembatumumab)Biosimilar Reference Antibody-GS40306

货号：GS40306

Glembatumumab vedotin (development code CDX-011) is an investigational antibody-drug conjugate (ADC) developed for the treatment of advanced breast cancer and melanoma. It is engineered by linking a fully human monoclonal antibody to a potent cytotoxic payload, monomethyl auristatin E (MMAE), via a cleavable linker. Glembatumumab vedotin functions as a targeted chemotherapy agent. The antibody component specifically binds to its target antigen, glycoprotein NMB (GPNMB), which is overexpressed on certain cancer cells. Upon binding, the ADC is internalized into the target cell, where the linker is cleaved, releasing the MMAE payload. MMAE disrupts microtubule networks, inhibits cell division, and induces apoptosis, leading to tumor cell death.